Press time:2016-08-02From:CR Sanjiu [ Font:BigMediumSmall]
China Food and Drug Administration (CFDA) recently issued the 7th Announcement of Protected Traditional Chinese Medicines (Announcement [2016] No. 125), with nine new TCMs developed by 10 pharmaceutical companies listed as grade-2 protected TCM, including “Er Xie Ting Ke Li” independently developed by China Resources Shenlu Pharmaceutical, a subsidiary wholly owned by China Resources Sanjiu.
China currently has a total of 317 protected traditional Chinese medicines, among which only 14, mostly cough drugs, are intended for use by children. Classified as a grade-B medicine in the national medical insurance, Er Xie Ting Ke Li is the first antidiarrheal drug for children to be officially recognized as a protected TCM in China, as well as one of the few protected TCMs developed exclusively for children. Li Lianda, a traditional Chinese medicine expert and academician at the China Engineering Academy, praised Er Xie Ting Ke Li for its “prescription precision, enhanced medicinal flavor and excellent clinical study results”, recommending it as “a useful drug for children”.
